Safinamide-d4-1

Safinamide-d4-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 μM) [1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8?μM) than at resting (IC50=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

Product Specifications

CAS Number

[2748522-33-8]

Product Name Alternative

FCE 26743-d4-1; EMD 1195686-d4-1

UNSPSC

12352005

Hazard Statement

H301, H318, H400

Target

Isotope-Labeled Compounds; Monoamine Oxidase

Type

Isotope-Labeled Compounds

Related Pathways

Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Purity

98.90

Solubility

10 mM in DMSO

Smiles

FC1=CC=CC(COC2=C([2H])C([2H])=C(C([2H])=C2[2H])CN[C@@H](C)C(N)=O)=C1

Molecular Formula

C17H15D4FN2O2

Molecular Weight

306.37

Precautions

H301, H318, H400

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67 (7 Suppl 2) :S18-23.|[3]Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50 (20), 4909-4916.|[4]Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364 (2) :198-206.